Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating
evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT …

Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

Compelling experimental evidence suggests that microglial activation is involved in the
spread of tau tangles over the neocortex in Alzheimer's disease (AD). We tested the …

Background Tauopathies are a class of neurodegenerative disorders characterized by
neuronal and/or glial tau-positive inclusions. Main body Clinically, tauopathies can present …

The functions of the neuronal microtubule-associated protein Tau in the central nervous
system are regulated by manifold posttranslational modifications at more than 50 sites. Tau …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss
and personality changes, eventually leading to dementia. The pathological hallmarks of AD …

The apolipoprotein E (APOE) gene is the strongest genetic risk factor for Alzheimer's
disease and directly influences tauopathy and tau-mediated neurodegeneration. ApoE4 has …

The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …